Clinical Trial Update: Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refractory Juvenile Dermatomyositis (RJDM) [Phase 1]

View source ↗

Summary

A Phase 1 trial is evaluating a CD19-targeted universal CAR-T therapy (UCAR-T) for refractory juvenile dermatomyositis and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatomyositis
• Juvenile Dermatomyositis

Drugs mentioned

• CD19-targeted universal CAR-T (UCAR-T)

Snippet

Sponsor: Chongqing Precision Biotech Co., Ltd | Conditions: Dermatomyositis, Juvenile, Dermatomyositis | Phase 1 | Status: RECRUITING